ConductScience.org, home

Library / Trials

PRP for Sexual Function

NCT07920900, Not applicable, Recruiting, Icahn School of Medicine at Mount Sinai

Trial 10

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitlePRP for Sexual FunctionClinicalTrials.gov
NCT numberNCT07920900ClinicalTrials.gov
StatusRecruitingClinicalTrials.gov
PhasesNot applicableClinicalTrials.gov
Enrollment60 participants, estimatedClinicalTrials.gov
Lead sponsorIcahn School of Medicine at Mount SinaiClinicalTrials.gov
ConditionsFemale Sexual Dysfunction, Sexual Dysfunction, PhysiologicalClinicalTrials.gov
InterventionsAutologous Platelet-Rich Plasma (PRP) Injection, Sterile saline injectionClinicalTrials.gov
First posted2026-11-06ClinicalTrials.gov
Last updated2026-11-06ClinicalTrials.gov

Registered outcomes 7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryChange in total score of The Female Sexual Function Index (FSFI)Baseline, 6 weeks, and 6 months after injection.
The Female Sexual Function Index (FSFI) is a 19-item questionnaire to evaluate female sexual function and dysfunction across 6 domains: desire, arousal, lubrication, orgasm, satisfaction, pain. Total scores range from 2.0-36.0; higher scores indicate better sexual function, and scores ≤26.5 indicate sexual dysfunction.
ClinicalTrials.gov
SecondaryChange in Female Sexual Distress Scale-Revised (FSDS-R) total scoreBaseline, 6 weeks, and 6 months after injection.
The Female Sexual Distress Scale-Revised (FSDS-R) is a 13-item questionnaire used to measure sexually related personal distress in adult women. Answers are scored on a scale of 0-4, with total scores ranging 0-52; higher scores indicate greater sexual distress, and scores ≥11 indicate clinically significant distress.
ClinicalTrials.gov
SecondaryPatient Global Impression of Improvement (PGI-I)6 weeks and 6 months after injection.
Patient Global Impression of improvement (PGI-I) is a single item scale assessing a patient's perception of change in their condition following treatment. The assessment is scored 1-7. Lower scores mean greater improvement. Scores of 1-3 are defined as a response.
ClinicalTrials.gov
SecondaryChange in FSFI domain scoresBaseline, 6 weeks, and 6 months from injection visit.
The Female Sexual Function Index (FSFI) is a 19-item questionnaire to evaluate female sexual function and dysfunction across 6 domains: desire, arousal, lubrication, orgasm, satisfaction, pain. Domains are scored 0 (or 1.2) to 6.0. Total scores range from 2.0-36.0. Higher scores indicate better sexual function.
ClinicalTrials.gov
SecondaryStress Urinary Incontinence Symptom FrequencyBaseline, 6 weeks, and 6 months from injection visit.Among participants reporting incontinence: leakage frequency with activity is scored on a scale of 0 (never) to 5 (several times per day). Higher scores indicate more frequent leakage.ClinicalTrials.gov
SecondaryVisual Analogue Scale (VAS)Day of injection - before speculum insertion, during injection, and within 5 minutes after injectionThe Visual Analogue Scale (VAS) is a single item questionnaire used to measure pain intensity. The assessment is scored on a scale of 0-10; higher scores indicate worse pain.ClinicalTrials.gov
SecondaryNumber of participants with adverse events.From injection through 6 months.Number of participants with treatment related adverse events post injection.ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Grants 0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

ProjectTitlePrincipal investigatorsOrganizationFunderFiscal yearsSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 5

FieldValueSource
Releasetrials-2026-11-12-0.4.0ClinicalTrials.gov
Release manifest SHA-2560f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov
NIH clinical studies file2026-11-13ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.4.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)